Drug Profile
Research programme: tyrosine kinase inhibitors - Onconova
Alternative Names: Bcr-Abl/JAK2 inhibitors - Onconova; HER1 inhibitors - Onconova; HER2 inhibitors - Onconova; HER2-inhibitors; ON 150030; ON01135; ON012380; ON01370; ON044580; ON045270; ON128030; ON128060Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Onconova Therapeutics
- Class Benzene derivatives; Pyrimidines; Quinazolines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Protein tyrosine kinase inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 08 Sep 2010 Preclinical development is ongoing in USA
- 08 Sep 2010 Research programme: tyrosine kinase inhibitors - Onconova is available for licensing as of 08 Sep 2010. http://www.onconova.com/partneringopportunities.shtml